Streetbeat News

Regulatory

MESO

Trading for MESO was halted and then resumed at 8:55 AM ET, with updated quotation resumption times following the release of news.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:55 pm

CMND

LAES

TGTX

TG Therapeutics projects Q1 BRIUMVI U.S. net product revenue to be between $41M and $46M, with an anticipated FY24 revenue of $220M to $260M. Clearmind Medicine has completed a Type A meeting with the FDA for its MEAI-based compound, CMND-100, aimed at treating Alcohol Use Disorder. SEALSQ has launched an innovative semiconductor provisioning service that promises to reduce lead times to just 4 weeks.

Portfolio Pulse from ryanfaloona@benzinga.com

January 10, 2024 | 1:44 pm

BTCUSD

A hacked tweet from the SEC about fake Bitcoin ETF approvals caused a market surge and subsequent crash, leading to over $220 million in liquidations. Long-position holders in Bitcoin suffered the most, with $133.5 million liquidated. The incident is the second-largest liquidation event of the year, affecting over 70,000 traders. ByBit, Binance, and OKX experienced significant liquidations. The event has raised concerns about the centralization of crypto and its deviation from its original purpose.

Portfolio Pulse from Murtuza Merchant

January 10, 2024 | 1:34 pm

SIDU

Sidus Space, Inc. has regained compliance with Nasdaq's minimum bid price requirement. The company's stock had previously fallen below the $1.00 minimum bid price per share that is required for continued listing on the Nasdaq. However, Sidus Space has since addressed this issue, and its stock is now meeting the necessary criteria.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:34 pm

COMS

COMSovereign Holding Corp. (NASDAQ:COMS) has regained its current filer status by filing its overdue quarterly reports for Q1, Q2, and Q3 of 2023. The company has reduced general and administrative expenses significantly through corporate streamlining, which has also improved its reporting processes. COMSovereign filed its 2022 annual report on December 7, 2023, after appraising goodwill and intangibles across its 16 operating units. The company has been restructuring, including selling off certain assets, to simplify its organization and reduce costs. The CEO, David Knight, emphasizes the company's focus on meeting Nasdaq and SEC requirements and supporting customer and partner needs, aiming for growth in 2024.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:23 pm

BBLG

Bone Biologics Corporation (BBLG) has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on The Nasdaq Capital Market. The company's stock had previously failed to meet the $1.00 minimum closing bid price for 30 consecutive days but has now maintained a price above $1.00 for 10 consecutive trading days as of January 4, 2024. Bone Biologics will be monitored by Nasdaq until June 28, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:22 pm

GSK

PFE

ViiV Healthcare, which is majority-owned by GSK and has Pfizer and Shionogi as stakeholders, has submitted a New Drug Submission for Cabotegravir to Health Canada for Pre-exposure Prophylaxis (PrEP). The submission is currently under priority review, which could expedite the approval process.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:16 pm

SECO

Secoo Holding Limited has received an additional delinquency letter from Nasdaq due to the late filing of its Form 6-K. The company is already non-compliant with Nasdaq's listing rules after failing to file its annual report on Form 20-F. Secoo has been given a deadline to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant an extension of up to 180 days to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:07 pm

MRTX

The European Commission has granted approval to Mirati Therapeutics' Krazati (Adagrasib) for the treatment of KRASG12C-mutated advanced non-small cell lung cancer in patients who have undergone at least one prior systemic therapy. This marks a significant regulatory milestone for Mirati Therapeutics, potentially impacting its market presence in Europe.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:04 pm

KERN

Akerna Corp. (NASDAQ:KERN) has announced a special meeting for stockholders to vote on a proposed merger with Gryphon Digital Mining, Inc. The meeting is scheduled for January 29, 2024. The SEC has declared effective Akerna's Form S-4 registration statement related to the merger. The merger aims to create a carbon-neutral bitcoin miner, with the new entity to be listed on Nasdaq under the ticker 'GRYP'. The transaction is subject to stockholder approval and customary closing conditions, with a target close date of January 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:04 pm